TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02492295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be administered as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice \<10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes. No more than 1.5mg/kg of propofol will be administered over this time period. After the sedation session is complete, patients will be allowed to wake up and will be monitored in the ED for at least another hour prior to discharge.
Study: NCT01207063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy and concurrent chemo-therapy
Description: Radiotherapy and concurrent chemo-therapy
Study: NCT02805582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10ml ropivacain 0.5%
Description: Ultrasound guided nerve block
Study: NCT03300388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (olive oil)
Description: Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
Study: NCT02343341

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Preschool Health Promotion Education Program
Study: NCT01083758

Intervention type: DRUG
Group type: OTHER
Intervention: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
Description: Topical suspension applied once daily for up to 8 weeks
Study: NCT02789124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carotid Doppler Measurement in response to passive leg raise
Description: The investigators will measure Carotid Flow time in the semi-recumbent position, then lay the patient flat and do a passive leg raise. The investigators will then meausre Carotid Flow Time at 1 minute, 2 minutes, and 3 minutes. Patients who have 10 % increase in stroke volume on the Flotrac / Vigileo monitor will be considered fluid responders. The investigators will try to identify an optimum % increase of Carotid Flow Time that can predict fluid responsiveness.
Study: NCT00808210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous repeating dose
Study: NCT04084067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: IV
Study: NCT00360282

Intervention type: DRUG
Group type: OTHER
Intervention: Rizatriptan
Description: 10 mg Rizatriptan in an unlabeled pill given once on one of two visits

Intervention type: DRUG
Group type: OTHER
Intervention: Rizatriptan
Description: 10 mg Rizatriptan in an unlabeled pill given once on one of two visits

Intervention type: DRUG
Group type: OTHER
Intervention: Rizatriptan
Description: 10 mg Rizatriptan in an unlabeled pill given once on one of two visits
Study: NCT02343341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preschool Health Promotion Education Program
Study: NCT03866993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK105
Description: IV infusion
Study: NCT02097368

Intervention type: PROCEDURE
Intervention: tongue strength measurement
Description: tongue strength measurement

Intervention type: PROCEDURE
Intervention: respiratory function measurement
Description: respiratory function measurement
Study: NCT03866993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT01773226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Protein Solution APS(TM)
Description: A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
Study: NCT01429259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meropenem
Description: meropenem 40mg/kg total body weight will be administered every 8 hours. Each infusion will be infused as a 3 hour infusion.
Study: NCT01323699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
Study: NCT01895504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ColoAssist
Description: Screening colonoscopy with the test instrument

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEI
Description: Colonoscopy with Olympus colonoscopes and MEI guidance
Study: NCT03882125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention
Description: Psychosocial intervention integrating mindfulness practice and cognitive behavioral relapse prevention approaches
Study: NCT01134874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard weight loss intervention
Description: In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard weight loss intervention plus technology
Description: In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology only
Description: One intervention telephone call per month, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
Study: NCT02341716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WA
Description: Walk advice with Nordic Poles and best medical treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SET
Description: Walk advice with Nordic Poles, best medical treatment and hospital-based supervised exercise therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HET
Description: Walk advice with Nordic Poles, best medical treatment and home-based supervised exercise therapy
Study: NCT03778294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorodopa F 18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT or PET/MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Receive proton beam RT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Drug
Study: NCT02152995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo iodine I-124 PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo iodine I-124 PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodine I 124
Description: Undergo iodine I-124 PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodine I 124
Description: Undergo iodine I-124 PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I-131
Description: Given PO
Study: NCT00360282

Intervention type: DRUG
Group type: OTHER
Intervention: Rizatriptan
Description: 10 mg Rizatriptan in an unlabeled pill given once on one of two visits
Study: NCT02397395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV) 150 mg
Description: Simeprevir (SMV) 150 milligram (mg) capsule orally, once daily for a duration of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 60 mg
Description: Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks.
Study: NCT03129334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LST Middle School Online
Description: The adapted intervention will (1) utilize both online e-learning module (self-guided) and classroom-based sessions (facilitator led) to address PDA and concurrent ATOD abuse; (2) positively change social norms and challenge positive expectancies regarding PDA and ATOD abuse; (3) discourage diversion of prescription medications; (4) enhance protective factors by building social and self-regulation skills through interactive learning and behavioral rehearsal scenarios; and (5) incorporate booster sessions.
Study: NCT00360282

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: In an unlabeled pill given once on one of two visits.
Study: NCT04425083

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04450615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability
Description: The exercise protocol consists of the following sets and repetitions, with a total duration of 5 weeks and a frequency of 3 sessions per week.~Dynamic exercises: 2 sets of 10 to 15 repetitions (each side) Isometric exercises: 2 sets of 5 to 15 seconds (each side) Week 1- As mentioned above Week 2- Add 1 set Week 3 - Add 5 seconds and 5 repetitions Week 4 - Add 1 set Week 5- Add 5 seconds and 5 repetitions
Study: NCT00880932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Alert
Study: NCT04419493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase (from modified manufacturing process)
Description: Alteplase, TPA-05

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase (from modified manufacturing process)
Description: Alteplase, TPA-05

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase (from current manufacturing process)
Description: Alteplase, TPA-02

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase (from current manufacturing process)
Description: Alteplase, TPA-02

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
Description: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
Description: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
Description: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
Description: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
Study: NCT03399734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Single oral dose of 1 x 4-mg perampanel tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Single 4-mg dose of perampanel fine granules
Study: NCT03726905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory muscles training
Description: 4 weeks respiratory muscles training aimed on respiratory muscles endurance and lengthening expiration time

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham respiratory muscles training
Description: 4 weeks sham respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: 12 weeks treadmill walking

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: aerobic training
Description: 12 weeks treadmill walking
Study: NCT04711564

Intervention type: OTHER
Intervention: Olive oil-based intravenous fat emulsions
Description: Parenteral nutrition planned according to the requirements of the patients is given for ten days.

Intervention type: OTHER
Intervention: Soybean-based intravenous fat emulsions
Description: Parenteral nutrition planned according to the requirements of the patients is given for ten days.
Study: NCT00993447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous at Day 0, 6 and 12 months

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis
Description: NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel®: 0.5 mL, Intramuscular at 12 months
Study: NCT04218929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Formula (SF)
Description: New infant formula for term infants fed ad lib

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Formula (CF)
Description: Commercially available infant formula for term infants fed ad lib
Study: NCT01957189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride and Tamsulosin
Description: 0.5mg dutasteride once a day on Day 1 Period A , and Day 5 Period C,0.2mg Tamsulosin once a day on Day 1 to Day 7 in Period B and Period C
Study: NCT03285282

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracolumber interfascial plane block
Description: Thoracolumber interfascial plane block versus placebo
Study: NCT03082963

Intervention type: DEVICE
Group type: OTHER
Intervention: Electrogram Morphology Mapping (EMR)
Description: Fifteen second AF recordings will be made using a multipolar electrode catheter to map the entire right atrium \& then the left atrium.
Study: NCT03551015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in the timing of components of usual care
Description: Bringing forward outpatient review, and cardiac rehabilitation after CABG by 3 and 4 weeks respectively.
Study: NCT00970502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib + celecoxib
Description: In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
Study: NCT00655187

Intervention type: OTHER
Intervention: Collection of information
Description: Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.

Intervention type: OTHER
Intervention: Collection of information
Description: Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.
Study: NCT02152995

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I-131
Description: Given PO
Study: NCT00655187

Intervention type: PROCEDURE
Intervention: Collection of stool samples
Description: Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.
Study: NCT01794325

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trans-radial
Description: Coronary angiography performed through trans-radial access
Study: NCT02097368

Intervention type: PROCEDURE
Intervention: swallowing tests
Description: swallowing tests

Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: Magnetic resonance imaging
Study: NCT01794325

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trans-femoral
Description: Coronary angiography performed through trans-femoral access
Study: NCT02576574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants received Pemetrexed 500 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Participants received Paclitaxel 200 mg/m\^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants received Gemcitabine 1250 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants received Gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
Study: NCT04564040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment A
Description: Participants will receive 100 mg AT suspension in water via NG tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment A
Description: Participants will receive 100 mg AT suspension in water via NG tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment B
Description: Participants will receive 100 mg acalabrutinib capsule suspension via NG tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment B
Description: Participants will receive 100 mg acalabrutinib capsule suspension via NG tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment C
Description: Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment C
Description: Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment D
Description: Participants will receive 100 mg AT orally.
Study: NCT02576574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL\*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
Study: NCT04564040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment D
Description: Participants will receive 100 mg AT orally.
Study: NCT02556632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin-based Gel
Description: Applied topically

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermatologic Complications Management
Description: Apply HPR Plus topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Apply placebo gel topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01732198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NU300

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Study: NCT02152995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo iodine I-124 PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo iodine I-124 PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT04494282

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic retrograde pancreatography
Description: Endoscopic cannulation of main pancreatic duct

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic retrograde pancreatography
Description: Endoscopic cannulation of main pancreatic duct